Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1

被引：12

作者：

Bringhen, Sara ^{[1
]}

Voorhees, Peter M. ^{[2
]}

Plesner, Torben ^{[3
,4
]}

Mellqvist, Ulf-Henrik ^{[5
]}

Reeves, Brandi ^{[6
]}

Sonneveld, Pieter ^{[7
]}

Byrne, Catriona ^{[8
]}

Nordstrom, Eva ^{[8
]}

Harmenberg, Johan ^{[8
]}

Obermuller, Jakob ^{[8
]}

Richardson, Paul G. ^{[9
]}

机构：

[1] Univ Torino, Div Haematol, AUO Citta Salute & Sci Torino, Turin, Italy

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[3] Vejle Hosp, Dept Haematol, Vejle, Denmark

[4] Univ Southern Denmark, Vejle, Denmark

[5] Boras Hosp, Dept Haematol, Boras, Sweden

[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[7] Erasmus MC, Canc Inst, Dept Haematol, Rotterdam, Netherlands

[8] Oncopeptides AB, Stockholm, Sweden

[9] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷 / 06期

关键词：

melflufen; melphalan flufenamide; relapsed; refractory multiple myeloma; multiple myeloma; ALKYLATING AGENT; POMALIDOMIDE; MULTICENTER; OUTCOMES;

D O I：

10.1111/bjh.17302

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An updated survival analysis was conducted for the Phase II study O-12-M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46-month median overall survival (OS) follow-up, melflufen plus dexamethasone had a median OS of 20 center dot 7 months (75th percentile OS, 47 center dot 5 months). The median time-to-next treatment for melflufen plus dexamethasone was 7 center dot 9 months. In summary, melflufen plus dexamethasone resulted in sustained long-term clinical benefit in patients with RRMM.

引用

页码：1105 / 1109

页数：5

共 15 条

[1]

[Anonymous], 2017, BLOOD S1

[2] In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells [J].

Chauhan, Dharminder ;

Ray, Arghya ;

Viktorsson, Kristina ;

Spira, Jack ;

Paba-Prada, Claudia ;

Munshi, Nikhil ;

Richardson, Paul ;

Lewensohn, Rolf ;

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2013, 19 (11) :3019-3031

[3]

Chen CC, 2017, J MANAG CARE SPEC PH, V23, P236, DOI 10.18553/jmcp.2017.23.2.236

[4] Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone [J].

Dimopoulos, Meletios A. ;

Weisel, Katja C. ;

Song, Kevin W. ;

Delforge, Michel ;

Karlin, Lionel ;

Goldschmidt, Hartmut ;

Moreau, Philippe ;

Banos, Anne ;

Oriol, Albert ;

Garderet, Laurent ;

Cavo, Michele ;

Ivanova, Valentina ;

Alegre, Adrian ;

Martinez-Lopez, Joaquin ;

Chen, Christine ;

Spencer, Andrew ;

Knop, Stefan ;

Bahlis, Nizar J. ;

Renner, Christoph ;

Yu, Xin ;

Hong, Kevin ;

Sternas, Lars ;

Jacques, Christian ;

Zaki, Mohamed H. ;

San Miguel, Jesus F. .

HAEMATOLOGICA, 2015, 100 (10) :1327-1333

[5] Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy [J].

Gandhi, Ujjawal H. ;

Cornell, Robert F. ;

Lakshman, Arjun ;

Gahvari, Zhubin J. ;

McGehee, Elizabeth ;

Jagosky, Megan H. ;

Gupta, Ridhi ;

Varnado, William ;

Fiala, Mark A. ;

Chhabra, Saurabh ;

Malek, Ehsan ;

Mansour, Joshua ;

Paul, Barry ;

Barnstead, Alyssa ;

Kodali, Saranya ;

Neppalli, Amarendra ;

Liedtke, Michaela ;

Narayana, Swapna ;

Godby, Kelly N. ;

Kang, Yubin ;

Kansagra, Ankit ;

Umyarova, Elvira ;

Scott, Emma C. ;

Hari, Parameswaran ;

Vij, Ravi ;

Usmani, Saad Z. ;

Callander, Natalie S. ;

Kumar, Shaji K. ;

Costa, Luciano J. .

LEUKEMIA, 2019, 33 (09) :2266-2275

[6] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study [J].

Kumar, S. K. ;

Lee, J. H. ;

Lahuerta, J. J. ;

Morgan, G. ;

Richardson, P. G. ;

Crowley, J. ;

Haessler, J. ;

Feather, J. ;

Hoering, A. ;

Moreau, P. ;

LeLeu, X. ;

Hulin, C. ;

Klein, S. K. ;

Sonneveld, P. ;

Siegel, D. ;

Blade, J. ;

Goldschmidt, H. ;

Jagannath, S. ;

Miguel, J. S. ;

Orlowski, R. ;

Palumbo, A. ;

Sezer, O. ;

Rajkumar, S. V. ;

Durie, B. G. M. .

LEUKEMIA, 2012, 26 (01) :149-157

[7] Multiple myeloma [J].

Kumar, Shaji K. ;

Rajkumar, Vincent ;

Kyle, Robert A. ;

van Duin, Mark ;

Sonneveld, Pieter ;

Mateos, Maria-Victoria ;

Gay, Francesca ;

Anderson, Kenneth C. .

NATURE REVIEWS DISEASE PRIMERS, 2017, 3

[8] Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials [J].

Lakshman, Arjun ;

Abeykoon, Jithma P. ;

Kumar, Shaji K. ;

Rajkumar, S. Vincent ;

Dingli, David ;

Buadi, Francis K. ;

Gonsalves, Wilson I. ;

Leung, Nelson ;

Dispenzieri, Angela ;

Kourelis, Taxiarchis V. ;

Go, Ronald S. ;

Lacy, Martha Q. ;

Hobbs, Miriam A. ;

Lin, Yi ;

Warsame, Rahma ;

Lust, John ;

Fonder, Amie L. ;

Hwa, Yi L. ;

Hayman, Suzanne R. ;

Russell, Stephen J. ;

Kyle, Robert A. ;

Gertz, Morie A. ;

Kapoor, Prashant .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (11) :1146-1155

[9]

Maciocia N, 2015, CLIN LYMPHOMA MYELOM, V15, pe288

[10]

Miettinen JJ, 2020, 25 EUR HEM ASS ANN C

← 1 2 →